Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

Allam Moore

Deportment of Pharmacy, Seoul National University, Gwanak-ro 38-gil, Seoul 08826, Korea

  • Mini Review   
    Cannabidiol′s Function in Disorders of Neurological Dysfunction: A Review
    Author(s): Allam Moore*

    A growing body of preclinical evidence suggests that certain cannabinoids, such as cannabidiol (CBD) and its engineered derivatives, may play a role in the myelinating processes. These cannabinoids are also promising small particles that could be developed as a treatment option for a variety of demyelinating conditions, including multiple sclerosis (MS), stroke and traumatic brain injury (TBI), which are three of the most common forms of demyelina Both the phytocannabinoid and its subordinates may be considered potential candidates for clinical use due to the properties shown by CBD and its fascinating human profile. We will summarize the most recent developments in the use of CBD and other cannabinoids as potential future medicines in this survey. It is anticipated that the coordinated effort of central participants, such as essential analysts, clinicians and .. Read More»
    DOI: 10.37421/2167-7689.2022.11.336

    Abstract HTML PDF

Google Scholar citation report
Citations: 533

Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

arrow_upward arrow_upward